	Application No.	Applicant(s)
Notice of Allowability	10/667,182	KATSU ET AL.
	Examiner	Art Unit
	Evelyn Huang	1625
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RID of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED or other appropriate commercement of the comm	in this application. If not included nunication will be mailed in due course. <b>THIS</b>
1. This communication is responsive to		
2. The allowed claim(s) is/are <u>15-31 and 36-38</u> .		
3. The drawings filed on are accepted by the Examiner.		
<ul> <li>4. Acknowledgment is made of a claim for foreign priority unall a) All b) Some* c) None of the: <ol> <li>Certified copies of the priority documents have</li> <li>Certified copies of the priority documents have</li> <li>Copies of the certified copies of the priority documents have</li> <li>International Bureau (PCT Rule 17.2(a)).</li> </ol> </li> <li>* Certified copies not received:</li> </ul>	been received. been received in Applicati	on No
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
<ul> <li>6.  CORRECTED DRAWINGS (as "replacement sheets") muse (a)  including changes required by the Notice of Draftspers <ol> <li>hereto or 2)  to Paper No./Mail Date</li> <li>including changes required by the attached Examiner's Paper No./Mail Date</li> </ol> </li> <li>Identifying indicia such as the application number (see 37 CFR 1.</li> </ul>	on's Patent Drawing Revie  Amendment / Comment of  84(c)) should be written on	or in the Office action of the drawings in the front (not the back) of
each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).  7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the		
attached Examiner's comment regarding REQUIREMENT		
Attachment(s)  1. Notice of References Cited (RTO 802)	5 □ Notice of U	oformal Datant Application (DTO 452)
<ol> <li>I Notice of References Cited (PTO-892)</li> <li>Draftperson's Patent Drawing Review (PTO-948)</li> </ol>	<u></u>	oformal Patent Application (PTO-152) Summary (PTO-413),
	Paper No	/Mail Date
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	8), 7. ⊠ Examiner's	s Amendment/Comment
4. Examiner's Comment Regarding Requirement for Deposit	<u> </u>	Statement of Reasons for Allowance
of Biological Material	9.	·

Art Unit: 1625

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Forman on 4-20-2005. During the interview, Applicants agreed to limit claim 38 to the method of treating gastroesophageal reflux disease to place the application in conditions for allowance.

The application has been amended as follows:

Claim 38, lines 1-4, delete 'gastrointestinal disease,.....or nausea'.

## REASONS FOR ALLOWANCE

2. The following is an examiner's statement of reasons for allowance:

Claims 15-31, 36-38 are allowed.

The 112 first paragraph rejection for claim 38 is withdrawn in view of the amendment limiting the claim to the method of treating gastroesophageal reflux disease, which finds support on pages 3, 31-32 of the specification. The scope of the claim is now commensurate with that of the objective enablement.

Uchida (6624162) discloses a 5 HT4 receptor binding piperidinyl-imidazopyridne compound similar to the instant. Uchida's piperidinyl is substituted by hydrogen, alkyl or alkoxyalkyl, whereas the alkyl on the piperidinyl in the instant compound is required to be substituted by one or two substituents not taught by Uchida. Absent is the motivation to modify the prior art compound to arrive at the instant invention.

3. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

Art Unit: 1625

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Evelyn Huang whose telephone number is 571-272-0686. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner

Art Unit 1625